MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

Core Insights - MetaVia Inc. is set to present its pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on February 25, 2026 [1] - The company is developing DA-1726, an oxyntomodulin analogue, for obesity treatment, and vanoglipel for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [1] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [1] - The company is publicly traded on Nasdaq under the ticker MTVA [1] Product Pipeline - DA-1726 is a dual agonist of glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), showing potential for superior weight loss and glucose control compared to selective GLP1R agonists [1] - In a Phase 1 trial, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction [1] - Vanoglipel is a G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of gut peptides GLP-1, GIP, and PYY, showing positive effects on liver inflammation and glucose metabolism in pre-clinical studies [1] - In a Phase 2a clinical study, vanoglipel exhibited direct hepatic action alongside glucose-lowering effects [1]